# Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

> **NCT02437279** · PHASE1 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Stage III Skin Melanoma

## Interventions

- **PROCEDURE:** Surgery of the tumor
- **DRUG:** Infusion with ipilimumab 3 mg/kg q3wks
- **DRUG:** Infusion with nivolumab 1 mg/kg q3wks

## Key facts

- **NCT ID:** NCT02437279
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-24
- **Primary completion:** 2018-06-28
- **Final completion:** 2025-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437279, "Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02437279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*